• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

孕激素受体(PR)的位点特异性O-连接N-乙酰葡糖胺化支持PR对乳腺癌中干扰素刺激基因(ISG)的抑制及肿瘤生长。

Site-specific O-GlcNAcylation of progesterone receptor (PR) supports PR attenuation of interferon stimulated genes (ISGs) and tumor growth in breast cancer.

作者信息

Saunders Harmony I, Holloran Sean M, Trinca Gloria M, Artigues Antonio, Villar Maite, Tinoco Julio C, Dias Wagner Barbosa, Werner Lauryn R, Chowanec Eilidh I, Heard Amanda, Chalise Prabhakar, Slawson Chad, Hagan Christy R

机构信息

Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA.

Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, Kansas, USA.

出版信息

J Biol Chem. 2024 Nov;300(11):107886. doi: 10.1016/j.jbc.2024.107886. Epub 2024 Oct 11.

DOI:10.1016/j.jbc.2024.107886
PMID:39395796
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11609360/
Abstract

Hormone receptor positive (HR+) breast cancer, defined by expression of estrogen receptor (ER) and/or progesterone receptor (PR), is the most commonly diagnosed type of breast cancer. PR alters the transcriptional landscape to support tumor growth in concert with, or independent of, ER. Understanding the mechanisms regulating PR function is critical to developing new strategies to treat HR+ breast cancer. O-linked β-N-acetylglucosamine (O-GlcNAc) is a posttranslational modification responsible for nutrient sensing that modulates protein function. Although PR is heavily posttranslationally modified, through both phosphorylation and O-GlcNAcylation, specific sites of O-GlcNAcylation on PR and how they regulate PR action have not been investigated. Using established PR-expressing breast cancer cell lines, we mapped several sites of O-GlcNAcylation on PR. RNA-sequencing after PR O-GlcNAc site mutagenesis revealed site-specific O-GlcNAcylation of PR is critical for ligand-independent suppression of interferon signaling, a regulatory function of PR in breast cancer. Furthermore, O-GlcNAcylation of PR enhances PR-driven tumor growth in vivo. Herein, we have delineated one contributing mechanism to PR function in breast cancer that impacts tumor growth and provided additional insight into the mechanism through which PR attenuates interferon signaling.

摘要

激素受体阳性(HR+)乳腺癌由雌激素受体(ER)和/或孕激素受体(PR)的表达所定义,是最常见的乳腺癌诊断类型。PR改变转录格局,与ER协同或独立支持肿瘤生长。了解调节PR功能的机制对于开发治疗HR+乳腺癌的新策略至关重要。O-连接的β-N-乙酰葡糖胺(O-GlcNAc)是一种负责营养感知的翻译后修饰,可调节蛋白质功能。尽管PR经过大量翻译后修饰,包括磷酸化和O-GlcNAc化,但PR上O-GlcNAc化的特定位点及其调节PR作用的方式尚未得到研究。利用已建立的表达PR的乳腺癌细胞系,我们绘制了PR上几个O-GlcNAc化位点。PR O-GlcNAc位点诱变后的RNA测序显示,PR的位点特异性O-GlcNAc化对于干扰素信号的非配体依赖性抑制至关重要,这是PR在乳腺癌中的一种调节功能。此外,PR的O-GlcNAc化增强了PR在体内驱动的肿瘤生长。在此,我们阐述了PR在乳腺癌中影响肿瘤生长的一种作用机制,并对PR减弱干扰素信号的机制提供了更多见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca2/11609360/39991e46ce3a/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca2/11609360/d8c2bba555bf/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca2/11609360/5e21fb362a5e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca2/11609360/6cc335f68b02/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca2/11609360/4c32f98d1cc4/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca2/11609360/39991e46ce3a/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca2/11609360/d8c2bba555bf/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca2/11609360/5e21fb362a5e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca2/11609360/6cc335f68b02/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca2/11609360/4c32f98d1cc4/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca2/11609360/39991e46ce3a/gr5.jpg

相似文献

1
Site-specific O-GlcNAcylation of progesterone receptor (PR) supports PR attenuation of interferon stimulated genes (ISGs) and tumor growth in breast cancer.孕激素受体(PR)的位点特异性O-连接N-乙酰葡糖胺化支持PR对乳腺癌中干扰素刺激基因(ISG)的抑制及肿瘤生长。
J Biol Chem. 2024 Nov;300(11):107886. doi: 10.1016/j.jbc.2024.107886. Epub 2024 Oct 11.
2
O-GlcNAc-Dependent Regulation of Progesterone Receptor Function in Breast Cancer.O-GlcNAc 依赖性调节乳腺癌中孕激素受体功能。
Horm Cancer. 2018 Feb;9(1):12-21. doi: 10.1007/s12672-017-0310-9. Epub 2017 Sep 19.
3
Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs.翻译后修饰的孕激素受体指导乳腺癌干细胞相关基因程序的配体特异性表达。
J Hematol Oncol. 2017 Apr 17;10(1):89. doi: 10.1186/s13045-017-0462-7.
4
Interferon-Stimulated Genes Are Transcriptionally Repressed by PR in Breast Cancer.干扰素刺激基因在乳腺癌中被 PR 转录抑制。
Mol Cancer Res. 2017 Oct;15(10):1331-1340. doi: 10.1158/1541-7786.MCR-17-0180. Epub 2017 Jul 6.
5
Decreasing O-GlcNAcylation affects the malignant transformation of MCF-7 cells via Hsp27 expression and its O-GlcNAc modification.O-GlcNAc 修饰减少通过 Hsp27 表达及其 O-GlcNAc 修饰影响 MCF-7 细胞的恶性转化。
Oncol Rep. 2018 Oct;40(4):2193-2205. doi: 10.3892/or.2018.6617. Epub 2018 Aug 1.
6
Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancer.孕激素受体依赖性的主要组织相容性复合体I类分子下调促进乳腺癌的肿瘤免疫逃逸和生长。
J Immunother Cancer. 2025 Mar 18;13(3):e010179. doi: 10.1136/jitc-2024-010179.
7
O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway.O-GlcNAcylation 通过调节 HIF-1 通路来调节癌症代谢和生存应激信号。
Mol Cell. 2014 Jun 5;54(5):820-31. doi: 10.1016/j.molcel.2014.04.026. Epub 2014 May 22.
8
O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.O-GlcNAcylation 诱导治疗抑制雌激素受体 α 的表达,并赋予人乳腺癌 MCF-7 细胞对 4-OH-他莫昔芬的耐药性。
PLoS One. 2013 Jul 11;8(7):e69150. doi: 10.1371/journal.pone.0069150. Print 2013.
9
Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression.磷酸化和 sumoylation 缺陷的孕激素受体在乳腺癌进展过程中驱动增殖性基因特征。
Breast Cancer Res. 2012 Jun 14;14(3):R95. doi: 10.1186/bcr3211.
10
Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III.孕激素受体对乳腺癌的抑制作用是通过其对雌激素受体和RNA聚合酶III的调节来介导的。
Cancer Res. 2017 Sep 15;77(18):4934-4946. doi: 10.1158/0008-5472.CAN-16-3541. Epub 2017 Jul 20.

引用本文的文献

1
Protein O-GlcNAcylation in reproductive biology and the impact of metabolic disease.生殖生物学中的蛋白质O-连接N-乙酰葡糖胺化修饰以及代谢性疾病的影响
Hum Reprod Update. 2025 Jun 26. doi: 10.1093/humupd/dmaf013.

本文引用的文献

1
On a sugar high: Role of O-GlcNAcylation in cancer.在糖基化作用下:O-连接的 N-乙酰葡萄糖胺化在癌症中的作用。
J Biol Chem. 2023 Nov;299(11):105344. doi: 10.1016/j.jbc.2023.105344. Epub 2023 Oct 12.
2
FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer.FOXA1 O-连接糖基化介导的转录开关调控乳腺癌的转移能力。
Sci Adv. 2023 Aug 18;9(33):eadg7112. doi: 10.1126/sciadv.adg7112.
3
How cancer cells make and respond to interferon-I.癌细胞如何产生和应对干扰素-I。
Trends Cancer. 2023 Jan;9(1):83-92. doi: 10.1016/j.trecan.2022.09.003. Epub 2022 Oct 8.
4
Mapping the O-GlcNAc Modified Proteome: Applications for Health and Disease.绘制O-连接的N-乙酰葡糖胺修饰蛋白质组图谱:健康与疾病中的应用
Front Mol Biosci. 2022 May 19;9:920727. doi: 10.3389/fmolb.2022.920727. eCollection 2022.
5
Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer.激素受体阳性和 HER2 阴性乳腺癌的靶向治疗现状。
Curr Oncol. 2021 May 11;28(3):1803-1822. doi: 10.3390/curroncol28030168.
6
Progesterone promotes immunomodulation and tumor development in the murine mammary gland.孕酮促进小鼠乳腺的免疫调节和肿瘤发展。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-001710.
7
O-GlcNAcylation and O-GlcNAc Cycling Regulate Gene Transcription: Emerging Roles in Cancer.O-连接的N-乙酰葡糖胺化修饰与O-连接的N-乙酰葡糖胺循环调控基因转录:在癌症中的新作用
Cancers (Basel). 2021 Apr 1;13(7):1666. doi: 10.3390/cancers13071666.
8
O-GlcNAcylation of MEK2 promotes the proliferation and migration of breast cancer cells.MEK2的O-连接N-乙酰葡糖胺化促进乳腺癌细胞的增殖和迁移。
Glycobiology. 2021 Jun 3;31(5):571-581. doi: 10.1093/glycob/cwaa103.
9
90 YEARS OF PROGESTERONE: Progesterone and progesterone receptors in breast cancer: past, present, future.90 年的孕激素:乳腺癌中的孕激素和孕激素受体:过去、现在和未来。
J Mol Endocrinol. 2020 Jul;65(1):T49-T63. doi: 10.1530/JME-20-0104.
10
Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancer.孕激素受体促进 STAT2 降解,从而抑制乳腺癌中的干扰素反应。
Oncoimmunology. 2020 Apr 30;9(1):1758547. doi: 10.1080/2162402X.2020.1758547. eCollection 2020.